WRBC
CERO

W.R. Berkley Corp’s CERo Therapeutics CERO Stock Holding History

W.R. Berkley Corp’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24
Closed -$519K – 172
2023
Q4 		$519K Hold
24
– – 0.04% 164
2023
Q3 		$513K Sell
24
-24
-50% -$520K 0.03% 195
2023
Q2 		$1.05M Sell
48
-2
-4% -$43.3K 0.06% 163
2023
Q1 		$1.06M Sell
50
-142
-74% -$2.99M 0.07% 146
2022
Q4 		$3.92M Hold
192
– – 0.21% 78
2022
Q3 		$3.88M Buy
192
+44
+30% +$886K 0.19% 95
2022
Q2 		$2.97M Hold
148
– – 0.15% 122
2022
Q1 		$2.97M Hold
148
– – 0.15% 130
2021
Q4 		$2.94M Buy
+148
New +$2.94M 0.16% 136

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PA
Pineridge Advisors St. Charles, Missouri $350M AUM 6.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

W.R. Berkley Corp's CERO Position: Q1 2024 in Review

W.R. Berkley Corp sold out of CERo Therapeutics (CERO) in Q1 2024, closing a stake of 24 shares — an estimated $519K sold.

W.R. Berkley Corp first reported a position in CERO in Q4 2021 and held it in 9 quarters. The position peaked at $3.92M in Q4 2022. 7 funds tracked by Wall St. Rank hold CERO as of Q1 2024.

  • W.R. Berkley Corp reported no remaining CERo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • W.R. Berkley Corp sold 24 CERo Therapeutics shares in Q1 2024, an estimated $519K.
  • W.R. Berkley Corp first reported a position in CERo Therapeutics in Q4 2021 and held it in 9 quarters.
  • W.R. Berkley Corp's CERo Therapeutics position peaked at $3.92M in Q4 2022.
  • 7 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2024.

Based on W.R. Berkley Corp's 13F filing for Q1 2024, filed 15 May 2024.